QQ客服 官方微博 反馈留言

	Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
	Fan Yangwei; Li Mengya; Ma Ke; Hu Yuan; Jing Jiayu; Shi Yu; Li Enxiao; Dong Danfeng
刊名	Cancer biology & therapy
	2018
页码	1-16
关键词	TAB1 doxorubicin resistance MDMX migration invasion MDM2 triple-negative breast cancer
ISSN号	1555-8576
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/2922005
专题	西安交通大学
推荐引用方式 GB/T 7714	Fan Yangwei,Li Mengya,Ma Ke,et al. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.[J]. Cancer biology & therapy,2018:1-16.
APA	Fan Yangwei.,Li Mengya.,Ma Ke.,Hu Yuan.,Jing Jiayu.,...&Dong Danfeng.(2018).Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway..Cancer biology & therapy,1-16.
MLA	Fan Yangwei,et al."Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.".Cancer biology & therapy (2018):1-16.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。